

EDNRB Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP6789b

Specification

EDNRB Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

<u>P24530</u>

EDNRB Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 1910

Other Names Endothelin B receptor, ET-B, ET-BR, Endothelin receptor non-selective type, EDNRB, ETRB

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP6789b was selected from the C-term region of human EDNRB. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures.

EDNRB Antibody (C-term) Blocking Peptide - Protein Information

Name EDNRB (<u>HGNC:3180</u>)

Synonyms ETRB

Function

Non-specific receptor for endothelin 1, 2, and 3. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.

Cellular Location

Cell membrane; Multi-pass membrane protein. Note=internalized after activation by endothelins.

Tissue Location

Expressed in placental stem villi vessels, but not in cultured placental villi smooth muscle cells



EDNRB Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

Blocking Peptides

EDNRB Antibody (C-term) Blocking Peptide - Images

EDNRB Antibody (C-term) Blocking Peptide - Background

EDNRB is a G protein-coupled receptor which activates a phosphatidylinositol-calcium second messenger system. Its ligand, endothelin, consists of a family of three potent vasoactive peptides: ET1, ET2, and ET3. Studies suggest that the multigenic disorder, Hirschsprung disease type 2, is due to mutations in the endothelin receptor type B gene.

EDNRB Antibody (C-term) Blocking Peptide - References

MacClellan, L.R., et.al., Stroke 40 (10), E550-E557 (2009)